| abstract |
The technology currently described provides compositions comprising aryl carboxylic acids chemically conjugated with hydrocodone (mortinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form prodrugs / novel hydrocodone compositions, including benzoates and heteroaryl carboxylic acids, which have a reduced potential for hydrocodone abuse. The present technology also provides methods for treating patients, pharmaceutical equipment and methods for synthesizing conjugates of the present technology. |